New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis

European Cytokine Network

Volumn 9, Issue 3, 1998, Pages 233-238

  Breedveld, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Rheumatoid arthritis; Turner necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; REVIEW; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; INTERLEUKIN-2; JOINTS; MODELS, BIOLOGICAL; PAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031738982     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Akil M, Amos R S. 1995. Rheumatoid arthritis - I: Clinical features and diagnosis. Br. Med. J. 310: 587.
2. Buckley C D. 1997. Science, medicine, and the future. Treatment of rheumatoid arthritis. Br. Med. J. 315: 236.
3. Grossman J M, Brahn E. 1997. Rheumatoid arthritis: current clinical and research directions. J. Women's Health 6: 627.
4. Akil M, Amos R S. 1995. Rheumatoid arthritis - II: Treatment. Br. Med. J. 310: 652.
5. Firestein G S, Zvaifler N J. 1997. Anticytokine therapy in rheumatoid arthritis. N. Engl. J. Med. 337: 195.
6. Koopman W J, Moreland L W. 1998. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann. Intern. Med. 128: 231.
7. Feldmann M. 1989. Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation, class II expression and cytokine production. Immunology 2: 66.
8. Brennan F M, Maini R N, Feldmann M. 1992. TNF-α - a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31: 293.
9. Fell H, Jubb RW. 1977. The effects of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum. 20: 1359.
10. Saklatvala J, Sarsfield Y, Townsend Y. 1985. Purification of two immunologically different leucocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J. Exp. Med. 162: 1208.
11. Saklatvala J. 1986. Tumour necrosis factor-α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547.
12. Harris E D. 1990. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322: 1277.
13. McQueen F M. 1997. The use of biologies in the treatment of rheumatoid arthritis (RA) - the good news and the bad news. Aust. N.Z. J. Med. 27: 175.
14. Handel M L, Watts C K W, Defazio A, Day R O, Sutherland R L. 1995. Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc. Natl. Acad. Sci. USA 92: 4497.
15. Dolhain R J E M, Tak P P, Dijkmans B A C, De Kuiper P, Breedveld F C, Miltenburg A M M. 1998. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol. 37: 502.
16. Breedveld F C. 1997. Early rheumatoid arthritis. Future treatment. Ballieres Clin. Rheumatol. 11: 83.
17. Campion G V, Lebsack M E, Lookabough J, Gordon G, Catalano M, and The IL-IRa Arthritis Study Group. 1996. Dose-range and dose-frequency study on recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 39: 1092.
18. Bresnihan B on behalf of the collaborating investigators, Lookabaugh J, Witt K, Musikic P. 1996. Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-IRa) in rheumatoid arthritis (RA): results of a randomized double-blind, placebo-controlled multicenter trial (abstract). Arthritis Rheum. 39: S73.
19. Watt I, Cobby M, Amgen rhIL-IRa Clinical Research Product Team. 1996. Recombinant human IL-1 receptor antagonist (rhIL-IRa) reduces the rate of joint erosion in rheumatoid arthritis (RA) (abstract). Arthritis Rheum. 39: S123.
20. Drevlow B E, Lovis R, Haag M A, Sinacore J M, Jacobs C, Blosche C, Landay A, Moreland L W, Pope R M. 1996. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39: 257.
21. Kyle V, Coughlan R J, Tighe H, Waldmann H, Hazleman B L. 1989. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann. Rheum. Dis. 48: 428.
22. 486-IL-2) in refractory rheumatoid arthritis. Arthritis Rheum. 38: 1177.
23. Sewell K L, Moreland L W, Cush J J, Furst D E, Woodworth T G, Mechan R T. 1993. Phase I/II double-blind dose-response trial of a second fusion toxin DAB389-IL-2 in rheumatoid arthritis (abstract). Arthritis Rheum. 36: S130.
24. + T cell clones and T cells. J. Immunol. 150: 4754.
25. Cohen S B A, Katsikis P D, Chu C Q, Thomssen H, Webb L M C, Maini R N, Londei M, Feldmann M. 1995. High levels of interleukin-10 production by activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum. 38: 946.
26. Davis D M, Charles P J, Potter A, Elliott M J, Feldmann M, Maini R N. 1996. TNF promotes cytokine inhibitory pathways in RA (abstract). Arthritis Rheum. 39: S224.
27. Elliott M J, Maini R N, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan F M, Walker J, Bijl H, Ghrayeb J, Woody J N. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 36: 1681.
28. Elliott M J, Maini R N, Feldmann M, Kalden J R, Antoni C, Smolen J S, Leeb B, Breedveld F C, Macfarlane J D, Bijl H, Woody J N. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105.
29. Elliott M J, Maini R N, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody J N. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125.
30. Camussi G, Lupia E. 1998. The future role of anti-tumour necrosis factor-(TNF) products in the treatment of rheumatoid arthritis. Drugs 55: 613.
31. Rankin E C C, Choy E H S, Kassimos D, Kingsley G H, Sopwith A M, Isenberg D A, Panayi G S. 1995. The therapeutic effects of an engineered human anti-tumor necrosis factor-alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34: 334.
32. Feldmann M, Elliott M J, Woody J N, Maini R N. 1997. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv. Immunol. 64: 283.
33. Bannwarth B, Vernhes J P, Schaeverbeke T, Dehais J. 1995. The facts about methotrexate in rheumatoid arthritis. Rev. Rheum. 62: 471.
34. LeGoff P, Koreichi A, Saraox A, Baron D. 1994. Lymphoma in a patient under low dose methotrexate for rheumatoid arthritis: a new case. Rev. Rheum. 61: 330.
35. Wolfe F, Mitchell D M, Sibley J T, Fries J F, Bloch D B, Williams C A, Spitz P W, Haga M, Kleinhecksel S M, Cathey M A. 1994. The mortality of rheumatoid arthritis. Arthritis Rheum. 37: 481.
36. Murray K M, Dahl S L. 1997. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann. Pharmacother. 31: 1335.
37. Mohler K M, Torrance D S, Smith C A, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer M B. 1993. Soluble tumor necrosis factor-(TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151: 1548.
38. Moreland L W, Margolies G, Heck L W Jr, Saway A, Blosch C, Hanna R, Koopman W J. 1996. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23: 1849.
39. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L, Ettlinger R E, Cohen S, Koopman W J, Mohler K, Widmer M B, Blosch C M. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141.